ATE432081T1 - Malaria-vakzine - Google Patents

Malaria-vakzine

Info

Publication number
ATE432081T1
ATE432081T1 AT03810941T AT03810941T ATE432081T1 AT E432081 T1 ATE432081 T1 AT E432081T1 AT 03810941 T AT03810941 T AT 03810941T AT 03810941 T AT03810941 T AT 03810941T AT E432081 T1 ATE432081 T1 AT E432081T1
Authority
AT
Austria
Prior art keywords
protein
hybrid
glutamate
antibody response
individual
Prior art date
Application number
AT03810941T
Other languages
English (en)
Inventor
Michael Theisen
Soren Jepsen
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Application granted granted Critical
Publication of ATE432081T1 publication Critical patent/ATE432081T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03810941T 2002-11-12 2003-11-06 Malaria-vakzine ATE432081T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK200201741A DK200201741A (da) 2002-11-12 2002-11-12 Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
DKPA200301307 2003-09-11
PCT/DK2003/000759 WO2004043488A1 (en) 2002-11-12 2003-11-06 Malaria vaccine

Publications (1)

Publication Number Publication Date
ATE432081T1 true ATE432081T1 (de) 2009-06-15

Family

ID=32313776

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03810941T ATE432081T1 (de) 2002-11-12 2003-11-06 Malaria-vakzine

Country Status (13)

Country Link
US (2) US7749507B2 (de)
EP (1) EP1567189B1 (de)
JP (1) JP4573773B2 (de)
CN (1) CN1741815B (de)
AT (1) ATE432081T1 (de)
AU (1) AU2003275949B2 (de)
BR (1) BR0315205A (de)
CA (1) CA2505724C (de)
DE (1) DE60327801D1 (de)
DK (2) DK200201741A (de)
ES (1) ES2326415T3 (de)
WO (1) WO2004043488A1 (de)
ZA (1) ZA200504415B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030161840A1 (en) * 1992-10-19 2003-08-28 Institut Pasteur Plasmodium falciparum antigens inducing protective antibodies
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
US20050112133A1 (en) * 2003-10-24 2005-05-26 Pierre Druilhe GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it
US7488489B2 (en) 2004-08-03 2009-02-10 Institut Pasteur Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies
KR101616572B1 (ko) * 2009-05-05 2016-05-11 카딜라 핼쓰캐어 리미티드 홍역-말라리아 조합 백신
CN102471361B (zh) 2009-07-15 2016-06-01 不列颠哥伦比亚大学 作为神经氨酸酶抑制剂的2,3-氟化糖苷及其作为抗病毒药物的用途
EP2385107B1 (de) 2010-05-03 2016-08-24 Institut Pasteur Auf Lentivirusvektor basierende immunologische Verbindungen gegen Malaria
DK2763694T3 (en) 2011-10-04 2018-04-16 Statens Seruminstitut Preparation of a cysteine-rich protein
WO2013082394A1 (en) * 2011-11-30 2013-06-06 The Regents Of The University Of California Immunogenic plasmodium falciparum antigen compositions and uses thereof
CN102533677B (zh) * 2012-01-10 2013-07-24 特菲(天津)生物医药科技有限公司 一种疟疾疫苗及其制备方法
CN107954963A (zh) 2012-01-19 2018-04-24 不列颠哥伦比亚大学 3’平伏氟取代的神经氨酸酶抑制剂化合物、组合物及其用作抗病毒剂的方法
CN105628928A (zh) * 2014-11-11 2016-06-01 深圳国际旅行卫生保健中心 可用于辅助诊断疟疾的试剂盒
CN105652009B (zh) * 2014-11-11 2018-04-24 中国科学院苏州纳米技术与纳米仿生研究所 可用于辅助诊断疟疾的试剂盒
KR20190044587A (ko) 2016-05-19 2019-04-30 아메드 에스.아이. 앨리 합성 말라리아 면역원, 이의 조합, 및 말라리아 감염을 예방하고 치료하기 위한 이의 용도
BR112019001115A2 (pt) * 2016-07-21 2019-06-25 Vac4All Pte Ltd proteínas de biofusão como vacinas anti-malária

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002811A1 (en) * 1988-09-16 1990-03-22 Statens Seruminstitut A malaria antigen
DK519188D0 (da) * 1988-09-16 1988-09-16 Statens Seruminstitut Kemisk forbindelse
US5231168A (en) * 1988-09-16 1993-07-27 Statens Seruminstitut Malaria antigen
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
AU3158900A (en) * 1999-02-25 2000-09-14 Smithkline Beecham Biologicals (Sa) Immunogens comprising a peptide and a carrier derived from h.influenzae protein
WO2002092628A2 (fr) * 2001-05-16 2002-11-21 Institut Pasteur Antigenes de plasmodium falciparum et leurs applications vaccinales et diagnostiques
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum

Also Published As

Publication number Publication date
ES2326415T3 (es) 2009-10-09
JP4573773B2 (ja) 2010-11-04
EP1567189A1 (de) 2005-08-31
DK200201741A (da) 2003-09-16
US20110020387A1 (en) 2011-01-27
US7749507B2 (en) 2010-07-06
HK1080754A1 (en) 2006-05-04
ZA200504415B (en) 2006-03-29
CA2505724C (en) 2015-06-30
US20060024324A1 (en) 2006-02-02
AU2003275949B2 (en) 2008-06-05
CA2505724A1 (en) 2004-05-27
EP1567189B1 (de) 2009-05-27
CN1741815A (zh) 2006-03-01
WO2004043488A1 (en) 2004-05-27
JP2006512926A (ja) 2006-04-20
DK1567189T3 (da) 2009-09-14
CN1741815B (zh) 2010-05-26
DE60327801D1 (de) 2009-07-09
BR0315205A (pt) 2005-08-16
AU2003275949A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
DK1567189T3 (da) Malariavaccine
CY1114030T1 (el) Ομοιογενη παρασκευασματα toy il-29
DE69434538D1 (de) Vaskularer endothelialer wachstumsfaktor 2
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
EP4585260A3 (de) Verfahren zur behandlung von hämophilie a
EP1732598A4 (de) Auslösung von zellulären immunantworten gegen den humanen papillovirus unter verwendung von peptid und nucleinsäure-zusammensetzungen
EP1490483A4 (de) In-vivo-einbau von nicht in der natur vorkommenden aminosäuren
DE60038567D1 (de) Modifiziertes gp100 und dessen verwendung
ATE412433T1 (de) Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
FR2744724B1 (fr) Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques
ATE286536T1 (de) Bindungs domänen von plasmodium vivax und plasmodium falciparum erythrozyten-bindenden proteinen
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
ATE399180T1 (de) Rekombinante polypeptide
ATE547529T1 (de) Materialien und verfahren im zusammenhang mit verbesserten impfstrategien
WO2003062374A3 (en) Synthetic genes for malarial proteins and methods of use
EA201171347A1 (ru) Комбинированная вакцина против кори и малярии
ATE214097T1 (de) Die ansteckung blockierende malariaimpfstoffe
DE60216523D1 (de) Herstellung und verwendung von mit verzweigten aminosäuren angereicherten sojaproteinhydrolysaten
ATE139537T1 (de) Gen zum kodieren eines antigens gegen menschlichen malaria impfstoff
WO2004033705A3 (en) Viral interferon antagonists and uses therefor
EP1802778A4 (de) Hcv-antigene zur mehrfachen epitopfusion mit modifizierten proteolytischen spaltungsorten und verwendungen davon
ATE351917T1 (de) Verfahren zur synthese von peptiden, peptidmimetika und proteinen
GB0220805D0 (en) Peptide monomers and protein structures
AU2003282159A8 (en) Chimeric recombinant protein and in vitro diagnosis of hiv
WO2003018807A1 (en) Nucleic acids showing difference in expression between hepatoblastoma anc normal liver

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties